Raymond James Financial’s Xenon Pharmaceuticals XENE Stock Holding History

Raymond James Financial’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.22M	Sell	86,461 -2,137	-2%	-$119K	﹤0.01%	2700
2026 Q1	$5.15M	Buy	88,598 +5,343	+6%	+$246K	﹤0.01%	2569
2025 Q4	$3.73M	Buy	83,255 +13,333	+19%	+$560K	﹤0.01%	2738
2025 Q3	$2.81M	Buy	69,922 +4,708	+7%	+$166K	﹤0.01%	2914
2025 Q2	$2.04M	Buy	65,214 +1,829	+3%	+$59.7K	﹤0.01%	3068
2025 Q1	$2.13M	Buy	63,385 +43,054	+212%	+$1.63M	﹤0.01%	2943
2024 Q4	$797K	Buy	+20,331	New	+$841K	﹤0.01%	3605

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Raymond James Financial's XENE Position: Q2 2026 in Review

Raymond James Financial reduced its Xenon Pharmaceuticals (XENE) stake by 2.4% in Q2 2026, selling an estimated $119K and leaving 86,461 shares worth $5.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2700.

Raymond James Financial first reported a position in XENE in Q4 2024 and has held it in 7 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Raymond James Financial held 86,461 shares of Xenon Pharmaceuticals worth $5.22M as of Q2 2026.
Raymond James Financial sold 2,137 Xenon Pharmaceuticals shares in Q2 2026, an estimated $119K.
Xenon Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2700 holding.
Raymond James Financial first reported a position in Xenon Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.